Evaluation of the Costs and Outcomes of COVID-19 Therapeutic Regimens in Hospitalized Patients in Shiraz

{ 'indexed': {'date-parts': [[2022, 9, 16]], 'date-time': '2022-09-16T06:14:06Z', 'timestamp': 1663308846727}, 'reference-count': 44, 'publisher': 'Springer Science and Business Media LLC', 'license': [ { 'start': { 'date-parts': [[2022, 9, 15]], 'date-time': '2022-09-15T00:00:00Z', 'timestamp': 1663200000000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.springer.com/tdm'}, { 'start': { 'date-parts': [[2022, 9, 15]], 'date-time': '2022-09-15T00:00:00Z', 'timestamp': 1663200000000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://www.springer.com/tdm'}], 'funder': [ { 'DOI': '10.13039/501100013041', 'name': 'Vice-Chancellor for Research, Shiraz University of Medical Sciences', 'doi-asserted-by': 'publisher', 'award': ['22409']}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'DOI': '10.1007/s40995-022-01351-0', 'type': 'journal-article', 'created': {'date-parts': [[2022, 9, 15]], 'date-time': '2022-09-15T14:27:56Z', 'timestamp': 1663252076000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Evaluation of the Costs and Outcomes of COVID-19 Therapeutic Regimens in Hospitalized Patients ' 'in Shiraz', 'prefix': '10.1007', 'author': [ {'given': 'Hooman', 'family': 'Behboodikhah', 'sequence': 'first', 'affiliation': []}, {'given': 'Eslam', 'family': 'Shorafa', 'sequence': 'additional', 'affiliation': []}, {'given': 'Iman', 'family': 'Karimzadeh', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mohsen', 'family': 'Moghadami', 'sequence': 'additional', 'affiliation': []}, {'given': 'Javad', 'family': 'Shahmohammadi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mohsen', 'family': 'Bayati', 'sequence': 'additional', 'affiliation': []}, {'given': 'Khosro', 'family': 'Keshavarz', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-4265-1499', 'authenticated-orcid': False, 'given': 'Manica', 'family': 'Negahdaripour', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2022, 9, 15]]}, 'reference': [ { 'key': '1351_CR1', 'doi-asserted-by': 'publisher', 'first-page': '106272', 'DOI': '10.1016/j.cct.2021.106272', 'volume': '101', 'author': 'ABA Al-Abdouh', 'year': '2021', 'unstructured': 'Al-Abdouh ABA, Barbarawi M, Jabri A, Kumar A, Fashanu OE et al (2021) ' 'Remdesivir for the treatment of COVID-19: A systematic review and ' 'meta-analysis of randomized controlled trials. Contemp Clin Trials ' '101:106272', 'journal-title': 'Contemp Clin Trials'}, { 'key': '1351_CR2', 'doi-asserted-by': 'publisher', 'first-page': '107245', 'DOI': '10.1016/j.intimp.2020.107245', 'volume': '91', 'author': 'A Bagheri', 'year': '2021', 'unstructured': 'Bagheri A, Moezzi SMI, Mosaddeghi P et al (2021) Interferon-inducer ' 'antivirals: potential candidates to combat COVID-19. Int Immunopharmacol ' '91:107245', 'journal-title': 'Int Immunopharmacol'}, { 'issue': '6', 'key': '1351_CR3', 'doi-asserted-by': 'publisher', 'first-page': '927', 'DOI': '10.1377/hlthaff.2020.00426', 'volume': '39', 'author': 'SM Bartsch', 'year': '2020', 'unstructured': 'Bartsch SM, Ferguson MC, McKinnell JA, O’Shea KJ, Wedlock PT (2020) The ' 'potential health care costs and resource use associated with COVID-19 in ' 'the United States. Health Aff 39(6):927–935', 'journal-title': 'Health Aff'}, { 'issue': '19', 'key': '1351_CR4', 'doi-asserted-by': 'publisher', 'first-page': '1813', 'DOI': '10.1056/NEJMoa2007764', 'volume': '383', 'author': 'JH Beigel', 'year': '2020', 'unstructured': 'Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC et al ' '(2020) Remdesivir for the treatment of Covid-19—final report. New Eng J ' 'Med 383(19):1813–1826', 'journal-title': 'New Eng J Med'}, { 'issue': '10', 'key': '1351_CR5', 'doi-asserted-by': 'publisher', 'first-page': '1192', 'DOI': '10.1016/j.eng.2020.03.007', 'volume': '6', 'author': 'Q Cai', 'year': '2020', 'unstructured': 'Cai Q, Yang M, Liu D, Chen J, Shu D et al (2020) Experimental treatment ' 'with favipiravir for COVID-19: an open-label control study. Engineering ' '6(10):1192–1198', 'journal-title': 'Engineering'}, { 'issue': '19', 'key': '1351_CR6', 'doi-asserted-by': 'publisher', 'first-page': '1787', 'DOI': '10.1056/NEJMoa2001282', 'volume': '382', 'author': 'B Cao', 'year': '2020', 'unstructured': 'Cao B, Wang Y, Wen D, Liu W, Wang J et al (2020) A trial of ' 'Lopinavir-Ritonavir in adults hospitalized with severe Covid-19. New Eng ' 'J Med 382(19):1787–1799', 'journal-title': 'New Eng J Med'}, { 'issue': '9', 'key': '1351_CR7', 'doi-asserted-by': 'publisher', 'first-page': '1788', 'DOI': '10.1093/gerona/glaa089', 'volume': '75', 'author': 'T Chen', 'year': '2020', 'unstructured': 'Chen T, Dai Z, Mo P, Li X, Ma Z et al (2020) Clinical characteristics ' 'and outcomes of older patients with coronavirus disease 2019 (COVID-19) ' 'in Wuhan, China: a single-centered. Retrosp Study J Gerontol: Series A ' '75(9):1788–1795', 'journal-title': 'Retrosp Study J Gerontol: Series A'}, { 'issue': '11', 'key': '1351_CR8', 'doi-asserted-by': 'publisher', 'first-page': '1409', 'DOI': '10.1016/j.jval.2020.07.002', 'volume': '23', 'author': 'DM Dawoud', 'year': '2020', 'unstructured': 'Dawoud DM, Soliman KY (2020) Cost-effectiveness of antiviral treatments ' 'for pandemics and outbreaks of respiratory illnesses, including ' 'COVID-19: a systematic review of published economic evaluations. Value ' 'Health 23(11):1409–1422', 'journal-title': 'Value Health'}, { 'key': '1351_CR9', 'doi-asserted-by': 'publisher', 'first-page': '1195', 'DOI': '10.1080/13543784.2020.1821645', 'volume': '29', 'author': 'SA Doggrell', 'year': '2020', 'unstructured': 'Doggrell SA (2020) Remdesivir, a remedy or a ripple in severe COVID-19? ' 'Expert Opin Investig Drugs 29:1195–1198', 'journal-title': 'Expert Opin Investig Drugs'}, { 'key': '1351_CR10', 'doi-asserted-by': 'publisher', 'first-page': '100794', 'DOI': '10.1016/j.drup.2021.100794', 'volume': '59', 'author': 'S Drożdżal', 'year': '2021', 'unstructured': 'Drożdżal S, Rosik J, Lechowicz K, Machaj F, Szostak B, Przybyciński J et ' 'al (2021) An update on drugs with therapeutic potential for SARS-CoV-2 ' '(COVID-19) treatment. Drug Resist Updat 59:100794', 'journal-title': 'Drug Resist Updat'}, { 'key': '1351_CR11', 'doi-asserted-by': 'publisher', 'first-page': '335', 'DOI': '10.3390/vaccines8020335', 'volume': '8', 'author': 'HA Elshabrawy', 'year': '2020', 'unstructured': 'Elshabrawy HA (2020) SARS-CoV-2: an update on potential antivirals in ' 'light of SARS-CoV antiviral drug discoveries. Vaccines 8:335', 'journal-title': 'Vaccines'}, { 'issue': '1', 'key': '1351_CR12', 'doi-asserted-by': 'publisher', 'first-page': '132', 'DOI': '10.1186/s12913-021-06126-8', 'volume': '21', 'author': 'M GhaffariDarab', 'year': '2021', 'unstructured': 'GhaffariDarab M, Keshavarz K, Sadeghi E, Shahmohamadi J, Kavosi Z (2021) ' 'The economic burden of coronavirus disease 2019 (COVID-19): evidence ' 'from Iran. BMC Health Serv Res 21(1):132', 'journal-title': 'BMC Health Serv Res'}, { 'issue': '24', 'key': '1351_CR13', 'doi-asserted-by': 'publisher', 'first-page': '2327', 'DOI': '10.1056/NEJMoa2007016', 'volume': '382', 'author': 'J Grein', 'year': '2020', 'unstructured': 'Grein J, Ohmagari N, Shin D, Diaz G, Asperges E et al (2020) ' 'Compassionate use of remdesivir for patients with severe Covid-19. N Eng ' 'J Med 382(24):2327–2336', 'journal-title': 'N Eng J Med'}, { 'issue': '5', 'key': '1351_CR14', 'doi-asserted-by': 'publisher', 'first-page': '2000547', 'DOI': '10.1183/13993003.00547-2020', 'volume': '55', 'author': 'WJ Guan', 'year': '2020', 'unstructured': 'Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS et al (2020) Comorbidity ' 'and its impact on 1590 patients with COVID-19 in China: a nationwide ' 'analysis. Eur Res J 55(5):2000547', 'journal-title': 'Eur Res J'}, { 'key': '1351_CR15', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.biopha.2021.112517', 'volume': '146', 'author': 'SMR Hashemian', 'year': '2022', 'unstructured': 'Hashemian SMR, Pourhanifeh MH, Hamblin MR, Shahrzad MK, Mirzaei H (2022) ' 'Rd inhibitors and COVID-19: Is molnupiravir a good option? Biomed ' 'Pharmacother 146:112517', 'journal-title': 'Biomed Pharmacother'}, { 'key': '1351_CR16', 'doi-asserted-by': 'publisher', 'author': 'Y Jo', 'year': '2021', 'unstructured': 'Jo Y, Jamieson L, Edoka I, Long L, Silal S et al (2021) ' 'Cost-effectiveness of remdesivir and dexamethasone for COVID-19 ' 'treatment in South Africa. Open Forum Inf Diss. ' 'https://doi.org/10.1093/ofid/ofab040', 'journal-title': 'Open Forum Inf Diss', 'DOI': '10.1093/ofid/ofab040'}, { 'issue': '2', 'key': '1351_CR17', 'doi-asserted-by': 'publisher', 'first-page': '102', 'DOI': '10.1016/j.jpha.2020.03.001', 'volume': '10', 'author': 'X Li', 'year': '2020', 'unstructured': 'Li X, Geng M, Peng Y, Meng L, Lu S (2020) Molecular immune pathogenesis ' 'and diagnosis of COVID-19. J Pharm Anal 10(2):102–108', 'journal-title': 'J Pharm Anal'}, { 'key': '1351_CR18', 'doi-asserted-by': 'publisher', 'first-page': '1864', 'DOI': '10.1002/jmv.26123', 'volume': '92', 'author': 'M Lotfi', 'year': '2020', 'unstructured': 'Lotfi M, Rezaei N (2020) SARS-CoV-2: a comprehensive review from ' 'pathogenicity of the virus to clinical consequences. J Med Virol ' '92:1864–1874', 'journal-title': 'J Med Virol'}, { 'key': '1351_CR19', 'doi-asserted-by': 'publisher', 'first-page': 'n2713', 'DOI': '10.1136/bmj.n2713', 'volume': '375', 'author': 'E Mahase', 'year': '2021', 'unstructured': 'Mahase E (2021) Covid-19: Pfizer’s paxlovid is 89% effective in patients ' 'at risk of serious illness, company reports. BMJ 375:n2713', 'journal-title': 'BMJ'}, { 'key': '1351_CR20', 'doi-asserted-by': 'publisher', 'first-page': '2005', 'DOI': '10.3201/eid2609.202095', 'volume': '26', 'author': 'RB Martines', 'year': '2020', 'unstructured': 'Martines RB, Ritter JM, Matkovic E, Gary J, Bollweg BC et al (2020) ' 'Pathology and pathogenesis of SARS-CoV-2 associated with fatal ' 'coronavirus disease, United States. Emerg Infect Dis 26:2005–2015', 'journal-title': 'Emerg Infect Dis'}, { 'key': '1351_CR21', 'doi-asserted-by': 'publisher', 'first-page': 'e005553', 'DOI': '10.1136/bmjopen-2014-005553', 'volume': '4', 'author': 'JAD Molina', 'year': '2014', 'unstructured': 'Molina JAD, Seow E, Heng BH, Chong WF, Ho B (2014) Outcomes of direct ' 'and indirect medical intensive care unit admissions from the emergency ' 'department of an acute care hospital: a retrospective cohort study. BMJ ' 'Open 4:e005553', 'journal-title': 'BMJ Open'}, { 'key': '1351_CR22', 'doi-asserted-by': 'publisher', 'first-page': '196', 'DOI': '10.1016/S2213-2600(20)30511-7', 'volume': '9', 'author': 'PD Monk', 'year': '2021', 'unstructured': 'Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN et al (2021) Safety ' 'and efficacy of inhaled nebulised interferon beta-1a (SNG001) for ' 'treatment of SARS-CoV-2 infection: a randomised, double-blind, ' 'placebo-controlled, phase 2 trial. Lancet Resp Med 9:196–206', 'journal-title': 'Lancet Resp Med'}, { 'key': '1351_CR23', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.2174/1574362416666210120104636', 'volume': '16', 'author': 'P Mosaddeghi', 'year': '2021', 'unstructured': 'Mosaddeghi P, Shahabinezhad F, Dehghani Z, Farahmandnejad M, Taghipour ' 'MJ, Moghadami M, Nezafat N, Masoompour SM, Negahdaripour M (2021) ' 'Therapeutic approaches for COVID-19 based on the interferon-mediated ' 'immune responses. Curr Signal Transduct Ther 16:1', 'journal-title': 'Curr Signal Transduct Ther'}, { 'issue': '45', 'key': '1351_CR25', 'doi-asserted-by': 'publisher', 'first-page': '14', 'DOI': '10.9734/jpri/2020/v32i4531088', 'volume': '32', 'author': 'M Nasir', 'year': '2021', 'unstructured': 'Nasir M, Perveen RA, Murshed M, Nazneen R, Talha KA (2021) Survival and ' 'biomarkers of COVID-19 patients treated with remdesivir and favipiravir ' 'in ICU during the peak of pandemic: a single center study in Bangladesh. ' 'JPRI 32(45):14–22', 'journal-title': 'JPRI'}, { 'key': '1351_CR26', 'first-page': '231', 'volume': '45', 'author': 'M Negahdaripour', 'year': '2020', 'unstructured': 'Negahdaripour M (2020) The rise and fall in therapeutic candidates for ' 'COVID-19. Iran J Med Sci 45:231–232', 'journal-title': 'Iran J Med Sci'}, { 'issue': '4', 'key': '1351_CR27', 'first-page': '235', 'volume': '46', 'author': 'M Negahdaripour', 'year': '2021', 'unstructured': 'Negahdaripour M (2021) Post-COVID-19 hyperglycemia: a concern in ' 'selection of therapeutic regimens. Iran J Med Sci 46(4):235–236', 'journal-title': 'Iran J Med Sci'}, { 'key': '1351_CR28', 'doi-asserted-by': 'publisher', 'first-page': '106924', 'DOI': '10.1016/j.intimp.2020.106924', 'volume': '88', 'author': 'H Owji', 'year': '2020', 'unstructured': 'Owji H, Negahdaripour M, Hajighahramani N (2020) Immunotherapeutic ' 'approaches to curtail COVID-19. Int Immunopharmacol 88:106924', 'journal-title': 'Int Immunopharmacol'}, { 'issue': '1', 'key': '1351_CR24', 'first-page': '9', 'volume': '7', 'author': 'SN Parashkouhi', 'year': '2021', 'unstructured': 'Parashkouhi SN, Mosaddeghi P, Bagheri A, Moezzi SMI, Hoseini SMF et al ' '(2021) The dual sides of interferon induction in COVID-19 treatment. ' 'Trend Pharm Sci 7(1):9–14', 'journal-title': 'Trend Pharm Sci'}, { 'key': '1351_CR29', 'doi-asserted-by': 'publisher', 'first-page': '870', 'DOI': '10.1016/j.chom.2020.05.008', 'volume': '27', 'author': 'A Park', 'year': '2020', 'unstructured': 'Park A, Iwasaki A (2020) Type I and Type III interferons–induction, ' 'signaling, evasion, and application to combat COVID-19. Cell Host ' 'Microbe 27:870–878', 'journal-title': 'Cell Host Microbe'}, { 'key': '1351_CR30', 'doi-asserted-by': 'publisher', 'first-page': '760', 'DOI': '10.1056/NEJMe2001126', 'volume': '382', 'author': 'S Perlman', 'year': '2020', 'unstructured': 'Perlman S (2020) Another decade, another coronavirus. N Eng J Med ' '382:760–762', 'journal-title': 'N Eng J Med'}, { 'key': '1351_CR31', 'doi-asserted-by': 'publisher', 'first-page': '320', 'DOI': '10.1038/s41586-020-3035-9', 'volume': '590', 'author': 'L Sanchez-Felipe', 'year': '2020', 'unstructured': 'Sanchez-Felipe L, Vercruysse T, Sharma S, Ma J, Lemmens V et al (2020) A ' 'single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate. ' 'Nature 590:320–325', 'journal-title': 'Nature'}, { 'issue': '7', 'key': '1351_CR32', 'first-page': '1211', 'volume': '49', 'author': 'M Sepandi', 'year': '2020', 'unstructured': 'Sepandi M, Taghdir M, Alimohamadi Y, Afrashteh S, Hosamirudsari H (2020) ' 'Factors associated with mortality in COVID-19 patients: a systematic ' 'review and meta-analysis. Iran J Public Health 49(7):1211–1221', 'journal-title': 'Iran J Public Health'}, { 'issue': '3', 'key': '1351_CR33', 'doi-asserted-by': 'publisher', 'first-page': '223', 'DOI': '10.1007/s12519-020-00343-7', 'volume': '16', 'author': 'K Shen', 'year': '2020', 'unstructured': 'Shen K, Yang Y, Wang T, Zhao D, Jiang Y et al (2020) Diagnosis, ' 'treatment, and prevention of 2019 novel coronavirus infection in ' 'children: experts’ consensus statement. W J Pediatr 16(3):223–231', 'journal-title': 'W J Pediatr'}, { 'key': '1351_CR34', 'unstructured': 'Singh J (2020) COVID-19 and its impact on society. Electron Res J Soc ' 'Sci. 2(I) Available at SSRN: https://ssrn.com/abstract=3567837'}, { 'key': '1351_CR35', 'doi-asserted-by': 'publisher', 'first-page': 'e048416', 'DOI': '10.1136/bmjopen-2020-048416', 'volume': '11', 'author': 'SKD Singh', 'year': '2021', 'unstructured': 'Singh SKD, Chugh A, Khera PS, Chugh VK (2021) Efficacy and safety of ' 'remdesivir in COVID-19 caused by SARS-CoV-2: a systematic review and ' 'meta-analysis. BMJ Open 11:e048416', 'journal-title': 'BMJ Open'}, { 'issue': '11', 'key': '1351_CR36', 'doi-asserted-by': 'publisher', 'first-page': '1048', 'DOI': '10.1001/jama.2020.16349', 'volume': '324', 'author': 'CD Spinner', 'year': '2020', 'unstructured': 'Spinner CD, Gottlieb RL, Criner GJ, ArribasLópez JR, Cattelan AM et al ' '(2020) Effect of remdesivir vs standard care on clinical status at 11 ' 'days in patients with moderate COVID-19: a randomized clinical trial. ' 'JAMA 324(11):1048–1057', 'journal-title': 'JAMA'}, { 'key': '1351_CR37', 'doi-asserted-by': 'publisher', 'author': 'P Srinivas', 'year': '2020', 'unstructured': 'Srinivas P, Sacha GL, Koval C (2020) Antivirals for COVID-19. Cleve Clin ' 'J Med. https://doi.org/10.3949/ccjm.87a.ccc030', 'journal-title': 'Cleve Clin J Med', 'DOI': '10.3949/ccjm.87a.ccc030'}, { 'issue': '3', 'key': '1351_CR38', 'doi-asserted-by': 'publisher', 'first-page': '155', 'DOI': '10.1038/s41579-020-00468-6', 'volume': '19', 'author': "P V'Kovski", 'year': '2021', 'unstructured': 'V’Kovski P, Kratzel A, Steiner S, Stalder H, Thiel V (2021) Coronavirus ' 'biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol ' '19(3):155–170', 'journal-title': 'Nat Rev Microbiol'}, { 'key': '1351_CR39', 'doi-asserted-by': 'publisher', 'first-page': '2039', 'DOI': '10.1056/NEJMoa012354', 'volume': '346', 'author': 'S Walmsley', 'year': '2002', 'unstructured': 'Walmsley S, Bernstein B, King M, Arribas J, Beall G et al (2002) ' 'Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV ' 'infection. N Eng J Med 346:2039–2046', 'journal-title': 'N Eng J Med'}, { 'key': '1351_CR40', 'doi-asserted-by': 'publisher', 'first-page': 'm2610', 'DOI': '10.1136/bmj.m2610', 'volume': '369', 'author': 'J Wise', 'year': '2020', 'unstructured': 'Wise J (2020) Covid-19: remdesivir is recommended for authorisation by ' 'European Medicines Agency. BMJ 369:m2610', 'journal-title': 'BMJ'}, { 'key': '1351_CR41', 'unstructured': 'World Bank (2020) PPP conversion factor, GDP (LCU per international $) - ' 'Iran, Islamic Rep. Available at ' 'https://data.worldbank.org/indicator/PA.NUS.PPP?locations=IR, Accessed ' 'at 22 May 2020'}, { 'issue': '1', 'key': '1351_CR42', 'doi-asserted-by': 'publisher', 'first-page': '413', 'DOI': '10.1186/s13054-020-03137-5', 'volume': '24', 'author': 'H Yamamura', 'year': '2020', 'unstructured': 'Yamamura H, Matsuura H, Nakagawa J, Fukuoka H, Domi H et al (2020) ' 'Effect of favipiravir and an anti-inflammatory strategy for COVID-19. ' 'Crit Care 24(1):413', 'journal-title': 'Crit Care'}, { 'issue': '15', 'key': '1351_CR44', 'doi-asserted-by': 'publisher', 'first-page': '1148', 'DOI': '10.1136/heartjnl-2020-316909', 'volume': '106', 'author': 'J Zhang', 'year': '2020', 'unstructured': 'Zhang J, Lu S, Wang X, Jia X, Li J et al (2020) Do underlying ' 'cardiovascular diseases have any impact on hospitalised patients with ' 'COVID-19? Heart 106(15):1148', 'journal-title': 'Heart'}, { 'key': '1351_CR45', 'doi-asserted-by': 'publisher', 'author': 'Q Zhou', 'year': '2020', 'unstructured': 'Zhou Q, Chen V, Shannon CP, Wei XS, Xiang X et al (2020) Interferon-α2b ' 'treatment for COVID-19. Front Immunol. ' 'https://doi.org/10.3389/fimmu.2020.01061', 'journal-title': 'Front Immunol', 'DOI': '10.3389/fimmu.2020.01061'}], 'container-title': 'Iranian Journal of Science and Technology, Transactions A: Science', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1007/s40995-022-01351-0.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1007/s40995-022-01351-0/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1007/s40995-022-01351-0.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 9, 15]], 'date-time': '2022-09-15T17:42:53Z', 'timestamp': 1663263773000}, 'score': 1, 'resource': {'primary': {'URL': 'https://link.springer.com/10.1007/s40995-022-01351-0'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 9, 15]]}, 'references-count': 44, 'alternative-id': ['1351'], 'URL': 'http://dx.doi.org/10.1007/s40995-022-01351-0', 'relation': {}, 'ISSN': ['1028-6276', '2364-1819'], 'subject': [ 'General Physics and Astronomy', 'General Mathematics', 'General Earth and Planetary Sciences', 'General Agricultural and Biological Sciences', 'General Chemistry'], 'container-title-short': 'Iran J Sci Technol Trans Sci', 'published': {'date-parts': [[2022, 9, 15]]}, 'assertion': [ { 'value': '18 April 2022', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '20 August 2022', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '15 September 2022', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, {'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Declarations'}}, { 'value': 'The authors declare no competing interests.', 'order': 2, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Conflict of Interest'}}, { 'value': 'This content has been made available to all.', 'name': 'free', 'label': 'Free to read'}]}